BMC Cancer

1. LIU Q, Jiao HY, Wang YY, Zhu LL, et al
   The tumor-suppressive function of the unique H domain of FCGBP and its potential as a therapeutic target in colorectal cancer.
   BMC Cancer. 2026 Feb 16. doi: 10.1186/s12885-026-15718.
   

   >> Share

   
   
2. ZHAO Q, Zhao K, Song J, Zhao W, et al
   Immune checkpoint inhibitor in third-line treatment of microsatellite stable metastatic colorectal cancer: an observational and retrospective study.
   BMC Cancer. 2026 Feb 16. doi: 10.1186/s12885-026-15740.
   

   >> Share

   
   
3. XIA W, Luo Z, Shan S, Chen J, et al
   Chemotherapy-related symptoms in colorectal cancer patients: A latent profile analysis.
   BMC Cancer. 2026 Feb 16. doi: 10.1186/s12885-026-15710.
   

   >> Share

   
   
4. GONJOBE MS, Dharsee N, Mduma E, Maunda KK, et al
   Oxaliplatin induced peripheral neuropathy and associated factors among colorectal cancer patients in Tanzania.
   BMC Cancer. 2026 Feb 18. doi: 10.1186/s12885-026-15769.
   

   >> Share

   
   

   
   BMJ Oncol

5. STORANDT MH, Sinicrope FA
   Deficient mismatch repair/microsatellite instability-high colorectal cancer: current treatment paradigms, limitations and future perspectives.
   BMJ Oncol. 2026;5:e000980.
   

   >> Share

   
   

   
   Br J Surg

6. TAN JH, Yan IWJ, Chang JHE, Khoo MSQ, et al
   Non-operative management of mismatch repair-deficient (dMMR) / micro satellite instability-high (MSI-H) colorectal cancer treated with immunotherapy: systematic review and meta-analysis.
   Br J Surg. 2026;113:znaf284.
   

   >> Share

   
   

   
   Cancer

7. 
   Correction to "Association of alcohol intake over the lifetime with colorectal adenoma and colorectal cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial".
   Cancer. 2026;132:e70324.
   

   >> Share

   
   

   
   Cancer Lett

8. HEROUX D, Sun XX, Zhang S, Sharifiaghdam M, et al
   Copper ionophores drive divergent responses to immune checkpoint inhibition across colorectal tumor models.
   Cancer Lett. 2026;641:218281.
   

   >> Share

   
   

   
   Cancer Res

9. RONDEAU V, Bansal S, Buttigieg MM, Zeng AGX, et al
   Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation.
   Cancer Res. 2026;86:845-857.
   

   >> Share

   
   

   
   Clin Res Hepatol Gastroenterol

10. BAJUL M, Meillat H, Fernandez B, Christou N, et al
    The "decompressing stoma - neoadjuvant Folfox chemotherapy - colectomy" strategy for non-metastatic obstructive colon cancer: A French retrospective multi-institutional case series.
    Clin Res Hepatol Gastroenterol. 2026 Feb 17:102787.
    

    >> Share

    
    

    
    Dig Dis

11. KIM SU, Nam SY, Jo J, Lee HS, et al
    Risk Factors for Rectal Neuroendocrine Tumors: A Population-Based Cohort Study of Sex-Specific Associations.
    Dig Dis. 2026;44:50-62.
    

    >> Share

    
    

    
    Int J Colorectal Dis

12. LOPES JL, Soares ASS, Mendes B, Tomada EP, et al
    Assessing the role of CT imaging in identifying candidates for neoadjuvant chemotherapy in right colon cancer: a critical analysis.
    Int J Colorectal Dis. 2026;41:66.
    

    >> Share

    
    

    
    J Am Coll Surg

13. WIGNAKUMAR A, Emile SH, Barnes S, Geraldi M, et al
    Development of a Predictive Calculator for the Need for Abdominoperineal Resection after Chemoradiation Therapy in Anal Squamous Cell Carcinoma.
    J Am Coll Surg. 2026;242:695-704.
    

    >> Share

    
    

    
    J Clin Oncol

14. MORRIS VK, Ciombor KK, Xiao L, Ochieng JK, et al
    NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.
    J Clin Oncol. 2026;44:497-507.
    

    >> Share

    
    

    
    J Natl Cancer Inst

15. RUTTER CM, Maerzluft CE, Matrajt L, Nascimento de Lima P, et al
    CRC-SPIN version 3.0: an updated policy model for colorectal cancer screening that includes the serrated pathway.
    J Natl Cancer Inst. 2026 Feb 16:djag037. doi: 10.1093.
    

    >> Share

    
    
16. HUANG BZ, Chen F, Bogumil D, Han S, et al
    Interaction of genetic and lifestyle risk scores on colorectal cancer risk across five racial and ethnic populations.
    J Natl Cancer Inst. 2026 Feb 16:djag045. doi: 10.1093.
    

    >> Share

    
    
17. 
    Correction to: Changing paradigms in colorectal cancer screening.
    J Natl Cancer Inst. 2026 Feb 17:djag010. doi: 10.1093.
    

    >> Share

    
    

    
    J Pathol

18. REITSAM NG, Jiang X, Liang J, Grosser B, et al
    Deep learning-based H&E-derived risk scores in colorectal cancer: associations with tumour morphology, biology, and predicted drug response.
    J Pathol. 2026 Feb 20. doi: 10.1002/path.70039.
    

    >> Share

    
    

    
    Oncogene

19. ACEVEDO M, Do F, El-Mortada F, Tanguay PL, et al
    The deubiquitinase USP17 regulates the expression and activity of the oncogenic driver beta-catenin in colorectal cancer.
    Oncogene. 2026 Feb 19. doi: 10.1038/s41388-026-03695.
    

    >> Share

    
    

    
    PLoS One

20. KIM HS, Kim J, Lee B, Lee Y, et al
    The role of exosomal miRNA-125b derived from colon cancer-associated fibroblasts in skeletal muscle cachexia.
    PLoS One. 2026;21:e0342052.
    

    >> Share

    
    
21. WANG Z, Ma L, Sun Z, Lv H, et al
    Elucidating key targets and mechanisms of diethyl phthalate-induced colorectal cancer through network toxicology and molecular docking.
    PLoS One. 2026;21:e0343038.
    

    >> Share

    
    

    
    Semin Oncol

22. MENYHART O, Muller D, Gyorffy B
    DNA methylation-mediated extracellular matrix gene silencing in colorectal cancer.
    Semin Oncol. 2026;53:152469.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share